6 terminated, 3 completed, 1 unknown, 1 withdrawn. 11 Phase 1, 3 Phase 2.
By phase and status
Follow Celularity Incorporated: new trials by email
Trials (filtered) newest first · largest first
All 11 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
CYNK-101, Pembrolizumab, Trastuzumab - Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Terminated | 1 | 2022-04-14 | 2024-12-12 |
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
CYNK-001 systemic and Intra cavity administration - Astrocytoma, Grade IV, Glioblastoma | Phase 1 / Phase 2 | Withdrawn | | 2021-09-01 | 2026-06-08 |
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
CYNK001-IV, CYNK001-IT - Astrocytoma, Grade IV, Giant Cell Glioblastoma | Phase 1 | Terminated | 3 | 2020-10-01 | 2022-08-10 |
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
CYNK-001 - Coronavirus, Coronavirus Infection | Phase 1 / Phase 2 | Terminated | 7 | 2020-09-02 | 2026-06-26 |
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
CYNK-001 - Multiple Myeloma, Neoplasm, Plasma Cell | Phase 1 | Unknown | 29 | 2020-05-12 | 2023-02-16 |
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
CYNK-001 - Leukemia, Leukemia, Myeloid | Phase 1 | Terminated | 27 | 2020-03-12 | 2024-12-12 |
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
rhIL-2, PNK-007 - Multiple Myeloma | Phase 1 | Completed | 15 | 2017-01-05 | 2020-07-22 |
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
PNK-007, Cyclophosphamide, Fludarabine - Leukemia, Myeloid, Acute | Phase 1 | Terminated | 10 | 2016-07-11 | 2020-07-22 |
Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers
PDA-002 - Peripheral Arterial Disease, Diabetic Foot Ulcer | Phase 1 | Completed | 15 | 2013-05-23 | 2026-06-04 |
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
PDA001, Vehicle Controlled Placebo - Crohns Disease | Phase 1 | Completed | 14 | 2013-03-01 | 2018-03-01 |
Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis
PDA001 (cenplacel-L) - Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis | Phase 1 | Terminated | 4 | 2011-09-01 | 2018-03-01 |
Conditions studied
Glioblastoma (2) · Hematologic Diseases (2) · Immune System Diseases (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Multiple Myeloma (2) · Neoplasm, Residual (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Plasma Cell (2) · Blood Protein Disorders (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Coronaviridae Infections (1) · Coronavirus Infections (1)
Interventions
Cyclophosphamide (2) · fludarabine (2) · Mesna (1) · Trastuzumab (1) · aldesleukin (1) · fludarabine phosphate (1) · pembrolizumab (1)
Countries
United States (10)
Top investigators
Adrian Kilcoyne, MD (2) · Monica E Luchi, MD (2) · Solveig Ericson, MD (2) · Corey Casper, MD MPH (1) · Sharmila Koppisetti, M.D (1) · Sharmila Koppisetti, MD (1)
Results publications
PMID 26054585, PMID 28133924